These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

364 related items for PubMed ID: 16105560

  • 1. Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent.
    Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ.
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):165-71. PubMed ID: 16105560
    [Abstract] [Full Text] [Related]

  • 2. Tigecycline: first of a new class of antimicrobial agents.
    Rose WE, Rybak MJ.
    Pharmacotherapy; 2006 Aug; 26(8):1099-110. PubMed ID: 16863487
    [Abstract] [Full Text] [Related]

  • 3. Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant gram-positive organisms.
    Garrison MW, Neumiller JJ, Setter SM.
    Clin Ther; 2005 Jan; 27(1):12-22. PubMed ID: 15763603
    [Abstract] [Full Text] [Related]

  • 4. The pharmacokinetic and pharmacodynamic profile of tigecycline.
    Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ.
    Clin Infect Dis; 2005 Sep 01; 41 Suppl 5():S333-40. PubMed ID: 16080071
    [Abstract] [Full Text] [Related]

  • 5. Tigecycline: a new glycylcycline for treatment of serious infections.
    Noskin GA.
    Clin Infect Dis; 2005 Sep 01; 41 Suppl 5():S303-14. PubMed ID: 16080069
    [Abstract] [Full Text] [Related]

  • 6. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
    Fritsche TR, Sader HS, Stilwell MG, Dowzicky MJ, Jones RN.
    Diagn Microbiol Infect Dis; 2005 Jul 01; 52(3):187-93. PubMed ID: 16105563
    [Abstract] [Full Text] [Related]

  • 7. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007).
    Nørskov-Lauritsen N, Marchandin H, Dowzicky MJ.
    Int J Antimicrob Agents; 2009 Aug 01; 34(2):121-30. PubMed ID: 19342205
    [Abstract] [Full Text] [Related]

  • 8. Metabolism, excretion, and pharmacokinetics of [14C]tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects.
    Hoffmann M, DeMaio W, Jordan RA, Talaat R, Harper D, Speth J, Scatina J.
    Drug Metab Dispos; 2007 Sep 01; 35(9):1543-53. PubMed ID: 17537869
    [Abstract] [Full Text] [Related]

  • 9. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections.
    Bradford PA, Weaver-Sands DT, Petersen PJ.
    Clin Infect Dis; 2005 Sep 01; 41 Suppl 5():S315-32. PubMed ID: 16080070
    [Abstract] [Full Text] [Related]

  • 10. Tigecycline: a critical analysis.
    Stein GE, Craig WA.
    Clin Infect Dis; 2006 Aug 15; 43(4):518-24. PubMed ID: 16838243
    [Abstract] [Full Text] [Related]

  • 11. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
    Vasilev K, Reshedko G, Orasan R, Sanchez M, Teras J, Babinchak T, Dukart G, Cooper A, Dartois N, Gandjini H, Orrico R, Ellis-Grosse E, 309 Study Group.
    J Antimicrob Chemother; 2008 Sep 15; 62 Suppl 1():i29-40. PubMed ID: 18684704
    [Abstract] [Full Text] [Related]

  • 12. Tigecycline: in-vitro performance as a predictor of clinical efficacy.
    Hawkey P, Finch R.
    Clin Microbiol Infect; 2007 Apr 15; 13(4):354-62. PubMed ID: 17359318
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Tigecycline: a new glycylcycline antimicrobial.
    Townsend ML, Pound MW, Drew RH.
    Int J Clin Pract; 2006 Dec 15; 60(12):1662-72. PubMed ID: 17109673
    [Abstract] [Full Text] [Related]

  • 15. In vitro activity of tigecycline against quinolone-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci.
    Garrison MW, Nuemiller JJ.
    Int J Antimicrob Agents; 2007 Feb 15; 29(2):191-6. PubMed ID: 17174074
    [Abstract] [Full Text] [Related]

  • 16. Tigecycline: a novel glycylcycline antibiotic.
    Zhanel GG, Karlowsky JA, Rubinstein E, Hoban DJ.
    Expert Rev Anti Infect Ther; 2006 Feb 15; 4(1):9-25. PubMed ID: 16441206
    [Abstract] [Full Text] [Related]

  • 17. Tigecycline: a glycylcycline antimicrobial agent.
    Doan TL, Fung HB, Mehta D, Riska PF.
    Clin Ther; 2006 Aug 15; 28(8):1079-1106. PubMed ID: 16982286
    [Abstract] [Full Text] [Related]

  • 18. Tigecycline.
    Pankey GA.
    J Antimicrob Chemother; 2005 Sep 15; 56(3):470-80. PubMed ID: 16040625
    [Abstract] [Full Text] [Related]

  • 19. Therapeutic applications of tigecycline in the management of complicated skin and skin structure infections.
    Grolman DC.
    Int J Infect Dis; 2007 May 15; 11 Suppl 1():S7-15. PubMed ID: 17603950
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.